ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
2,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
2,2,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,1,Product after taste,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
3,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
3,3,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
4,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,3,Glioma,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
5,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
6,1,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
7,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
7,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
7,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
8,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
8,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Thyroid cancer,Thyroid neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
10,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
11,1,Escherichia infection,Escherichia infections,Bacterial infectious disorders,Infec,N
11,2,Food refusal,Appetite disorders,Appetite and general nutritional disorders,Metab,N
11,3,Wound,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
12,1,Nephrocalcinosis,Renal lithiasis,Urolithiases,Renal,N
13,1,Adenocarcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
14,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,2,Pelvic neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
15,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
15,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
15,3,Papillary thyroid cancer,Thyroid neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
15,4,Papillary thyroid cancer,Thyroid neoplasms malignant,Endocrine neoplasms malignant and unspecified,Neopl,N
16,1,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
17,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
